According to a recent LinkedIn post from Research Grid, the company is drawing attention to growing concerns around the use of certain artificial intelligence approaches in clinical trials. The post points to an industry trend where legacy technology vendors are rapidly embedding AI into platforms that were not originally built with AI capabilities in mind.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post suggests that this rush has led to widespread adoption of black-box AI models, with agentic AI systems also emerging across vendors. It indicates that these models may pose heightened safety, operational, and regulatory risks in the clinical trial setting, and references commentary from Dr. Amber Michelle H. to elaborate on these issues.
For investors, the post may signal that Research Grid is positioning itself as a more cautious or differentiated player in clinical-trial technology, potentially emphasizing transparency and regulatory alignment in its AI strategy. If the company can offer AI-enabled solutions that mitigate the risks described, it could strengthen its competitive standing with sponsors and CROs that are sensitive to compliance and patient-safety concerns.
The focus on risk around black-box and agentic AI also underscores the likelihood of tighter scrutiny from regulators and trial sponsors, which could reshape procurement criteria across the clinical technology landscape. Companies that align their products with emerging expectations for explainability and auditability may be better placed to capture budget as AI adoption in clinical research scales.